CN109908165B - Composition containing tripterine and application thereof - Google Patents
Composition containing tripterine and application thereof Download PDFInfo
- Publication number
- CN109908165B CN109908165B CN201910342802.3A CN201910342802A CN109908165B CN 109908165 B CN109908165 B CN 109908165B CN 201910342802 A CN201910342802 A CN 201910342802A CN 109908165 B CN109908165 B CN 109908165B
- Authority
- CN
- China
- Prior art keywords
- tripterine
- topiramate
- composition
- mice
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention provides a composition containing tripterine, and relates to the technical field of medicines. The composition comprises topiramate and tripterine, wherein the mass ratio of the topiramate to the tripterine is (2-800) x 103:1. The topiramate and the tripterine are combined, so that the dosage of the two medicines can be reduced, the side effects of the two medicines can be obviously reduced, and meanwhile, the weight can be more obviously reduced, the insulin sensitivity can be improved, and the lipid metabolism can be optimized. The composition of the invention can still play the roles of obviously reducing the weight, improving the insulin sensitivity and optimizing the lipid metabolism when the dosage is halved.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a tripterine-containing composition and application thereof.
Background
With the increasing living standard of people, obesity and related diseases such as diabetes, hyperlipidemia, fatty liver, cardiovascular and cerebrovascular diseases and the like which are commonly seen in developed countries in the west and are related to energy metabolism become important diseases which threaten the health of Chinese people more and more. According to statistics, the incidence rates of overweight and obesity in Chinese adults are 30.6% and 12.0% respectively.
The metabolic syndrome is a group of clinical syndromes which are caused by aggregation of central obesity, hyperglycemia, hyperlipidemia, hypertension and the like and seriously affect the health of an organism, is clinically characterized by the combined appearance of various metabolic diseases, and is a group of risk factors which are related to each other in metabolism. The pathogenesis of each component is complex and is not fully understood at present, but central obesity and insulin resistance are well-recognized important pathogenic factors.
Obesity is the result of a combination of genetic and environmental factors, caused by the body's energy intake exceeding energy expenditure. Obesity has a close relationship with insulin. Research proves that obesity can cause insulin resistance, and the chronic low-grade inflammatory state of the body caused by obesity directly influences the pancreatic islet function and insulin signal transmission. According to thermodynamics, any means of treating obesity must reduce energy intake, effectively increase energy expenditure, either or both. While the principles seem simple, the treatment of obesity remains challenging. Currently clinically accepted regimens for the treatment of obesity include diet, exercise, medication to reduce calorie intake and absorption, and surgical treatment of extremely obese patients. However, only a small percentage of people can sustain long-term weight loss through diet and exercise, and in addition, although the surgical treatment effect is significant, the surgical risk is still prohibitive for many people.
Disclosure of Invention
In view of the above, the present invention is directed to a composition containing tripterine and its application. The composition containing the tripterine provided by the invention can be used for treating obesity and metabolic syndrome, and has obvious effects of losing weight, reducing blood sugar and improving lipid metabolism.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a tripterine-containing composition, which comprises topiramate and tripterine, wherein the mass ratio of the topiramate to the tripterine is (2-800) x 103:1。
The invention provides application of the composition in the technical scheme in preparation of a medicine for treating metabolic syndrome.
The invention provides application of the composition in the technical scheme in preparation of hypoglycemic drugs.
The invention provides application of the composition in the technical scheme in preparing a medicine for reducing serum and liver triglyceride.
The invention provides application of the composition in the technical scheme in preparation of a serum cholesterol lowering drug.
The invention provides application of the composition in the technical scheme in preparation of a medicine for treating obesity.
The invention provides application of the composition in the technical scheme in preparation of a medicament for treating diabetes.
Preferably, the dosage form of the medicament comprises tablets, powders, granules, capsules, oral liquid and sustained release agents.
The invention provides a composition containing tripterine and application thereof. According to the invention, the fat mouse which is modeled by high-fat feeding is used as a research object, and the experimental result of the embodiment 1 shows that the composition can still play the roles of obviously reducing the weight, improving the insulin sensitivity and optimizing the lipid metabolism when the dosage is halved. By combined application, the dosage of the two medicines can be reduced, the side effect of the two medicines can be obviously reduced, and simultaneously the weight can be more obviously reduced, the insulin sensitivity can be improved, and the lipid metabolism can be optimized.
Drawings
FIG. 1 is a graph showing the effect of topiramate dry-control group, tripterine dry-control group, topiramate combined tripterine dose halved group and blank solvent control group on the body weight of mice; wherein ND represents blank solvent for normal diet administration; HFD stands for high-fat diet administration of the blank solvent; HFD + TPM represents high fat diet administration of topiramate; HFD + CEL stands for high fat diet given dried tripterine; HFD + T + C represents high fat diet given at each dose halved tripterine and topiramate;
FIG. 2 is a graph showing the effect of groups ND, HFD + TPM, HFD + CEL, and HFD + T + C on the random blood glucose level of mice;
FIG. 3 is a graph showing the effect of groups ND, HFD + TPM, HFD + CEL, and HFD + T + C on mouse serum triglyceride;
FIG. 4 is a graph showing the effect of groups ND, HFD + TPM, HFD + CEL, and HFD + T + C on serum cholesterol in mice;
FIG. 5 is a graph showing the effect of groups ND, HFD + TPM, HFD + CEL, and HFD + T + C on mouse hepatic triglyceride.
Detailed Description
The invention provides a composition containing tripterineThe composition comprises topiramate and tripterine, wherein the mass ratio of the topiramate to the tripterine is (2-800) x 103:1。
In the invention, the mass ratio of the topiramate to the tripterine is (2-800) x 1031, preferably (10 to 600). times.1031, more preferably 400X 103:1. The sources of the topiramate and the tripterine are not particularly limited, and the conventional commercial products are adopted.
The invention provides application of the composition in the technical scheme in preparation of a medicine for treating metabolic syndrome. The invention has no special limitation on the types of the auxiliary materials for preparing the medicament for treating the metabolic syndrome, and the auxiliary materials for preparing the medicament by the conventional method are adopted. The preparation form of the medicament for treating the metabolic syndrome is not particularly limited, and tablets, powders, granules, capsules, oral liquid and sustained release agents are preferred.
The invention provides application of the composition in the technical scheme in preparation of hypoglycemic drugs. The invention has no special limitation on the types of the auxiliary materials for preparing the hypoglycemic drug, and the auxiliary materials for preparing the hypoglycemic drug can be prepared by adopting the conventional auxiliary materials. The dosage form of the preparation of the hypoglycemic drug is not particularly limited, and tablets, powders, granules, capsules, oral liquid and sustained release agents are preferred.
The invention provides application of the composition in the technical scheme in preparing a medicine for reducing serum and liver triglyceride. The invention has no special limitation on the types of the auxiliary materials for preparing the medicines for reducing blood serum and liver triglyceride, and the auxiliary materials for preparing the medicines for reducing blood serum and liver triglyceride are prepared by adopting the conventional method. The dosage form of the medicine for reducing serum and liver triglyceride is not specially limited, and tablets, powder, granules, capsules, oral liquid and sustained release agents are preferred.
The invention provides application of the composition in the technical scheme in preparation of a serum cholesterol lowering drug. The invention has no special limitation on the types of the auxiliary materials for preparing the serum cholesterol reducing medicine, and the auxiliary materials for preparing the serum cholesterol reducing medicine are prepared by adopting the conventional method. The dosage form of the medicine for reducing serum cholesterol is not specially limited, and tablets, powder, granules, capsules, oral liquid and sustained release agents are preferred.
The invention provides application of the composition in the technical scheme in preparation of a medicine for treating obesity. The invention has no special limitation on the types of the auxiliary materials for preparing the medicament for treating obesity, and the auxiliary materials for preparing the medicament for treating obesity conventionally are adopted. The dosage form of the medicament for treating obesity is not particularly limited, and tablets, powders, granules, capsules, oral liquid and sustained release agents are preferred.
The invention provides application of the composition in the technical scheme in preparation of a medicament for treating diabetes. The invention has no special limitation on the types of the auxiliary materials for preparing the medicament for treating diabetes, and the auxiliary materials for preparing the medicament for treating diabetes by a conventional method are adopted. The dosage form of the medicament for treating diabetes is not particularly limited, and tablets, powders, granules, capsules, oral liquid and sustained-release agents are preferred.
The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The mice were 8 week old male, healthy SPF grade mice purchased from the animal center of the department of medicine, beijing university.
The mouse breeding conditions are 22 +/-0.5 ℃ and 12 h/12 h alternating light and shade.
The experimental data are expressed as mean ± sem, and the topiramate combined with a halved dose of tripterine compared to a high-fat diet blank solvent control group, P <0.05, P <0.01, P <0.001, and n ═ 6.
The effect of topiramate in combination with celastrol on the food intake and body weight of obese mice on high fat diet;
after 7 days of adaptive culture by using common feed, dividing the mice into two groups, continuously feeding the mice with the common feed for one group, and feeding the mice with the high-fat feed for 2 weeks, wherein the average weight of the mice on the high-fat diet is 28.2g, and the weight of the mice on the normal diet is 24.1 g; then, the high-fat diet mice are randomly divided into an A topiramate dry pretreatment group, a B tripterine dry pretreatment group, a C topiramate combined tripterine half-reduced group and a D blank solvent control group, and the grouping intraperitoneal injection is started: group A is given 40mg/kg/D of topiramate, group B is given 1 mu g/kg/D of tripterine, group C is given 20mg/kg/D of topiramate and 0.5 mu g/kg/D of tripterine, and group D is given blank solvent control; the mice fed with the normal feed were given a blank solvent control.
DMSO is used as solvent as food additive, and the above materials are dissolved in the solvent.
Calculating the food intake of the mice: the weight of the food left after the mice had eaten was measured daily, and the daily food intake was calculated by subtracting the weight of the food left from the daily food intake.
During the experiment, the body weight and food weight of the mice were measured daily from the first day of administration. There was no significant difference in body weight between the two groups of mice before administration, and on day 7, the body weight of mice in the group with half-reduced doses of topiramate in combination with tripterine and the blank solvent control group began to differ and gradually increased with time (see fig. 1). The experimental result shows that the topiramate and the tripterine can obviously inhibit the weight gain of the high-fat diet mice.
No obvious difference in random blood sugar was observed in four groups of mice before administration, and with intraperitoneal injection, blood sugar began to appear in mice with half-reduced doses of topiramate and tripterine and blank solvent control groups (as shown in FIG. 2). Experimental results show that the combination of topiramate and tripterine can obviously reduce the blood sugar of mice with high-fat diet.
After the intraperitoneal injection administration is finished, the values of serum triglyceride, cholesterol and liver triglyceride of the mice are respectively monitored, and the result shows that the combination of topiramate and tripterine can obviously reduce the serum triglyceride P of the mice to be less than 0.01, and simultaneously, the lipid-lowering effect is superior to that of the respective single use (as shown in figure 3); the combination of topiramate and tripterine can obviously reduce the serum cholesterol of mice, and the cholesterol reduction effect is also obviously superior to that of P <0.01 (as shown in figure 4) when the two medicines are used independently; the combination of topiramate and tripterine can obviously reduce liver triglyceride P of mice to be less than 0.01 (as shown in figure 5); thus, the combination of topiramate and tripterine has the function of improving hyperlipidemia, and the curative effects are obviously better than those of any one of the medicines used alone.
The results of example 1 show that the composition of topiramate and tripterine can obviously reduce the dosage of topiramate and tripterine used independently, and can achieve the effect superior to that of topiramate and tripterine used independently.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (5)
1. A composition containing tripterine is characterized by comprising topiramate and tripterine, wherein the mass ratio of the topiramate to the tripterine is 40 x 103:1。
2. Use of the composition of claim 1 for the preparation of a medicament for the treatment of hyperlipidemia.
3. Use of a composition according to claim 1 for the manufacture of a medicament for the treatment of obesity.
4. The use of the composition of claim 1 for the preparation of a medicament for the treatment of diabetes.
5. The use according to any one of claims 2 to 4, wherein the medicament is in the form of any one of tablets, powders, granules, capsules, oral liquids and sustained-release agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910342802.3A CN109908165B (en) | 2019-04-26 | 2019-04-26 | Composition containing tripterine and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910342802.3A CN109908165B (en) | 2019-04-26 | 2019-04-26 | Composition containing tripterine and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109908165A CN109908165A (en) | 2019-06-21 |
| CN109908165B true CN109908165B (en) | 2020-06-09 |
Family
ID=66978510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910342802.3A Active CN109908165B (en) | 2019-04-26 | 2019-04-26 | Composition containing tripterine and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109908165B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112294824B (en) * | 2019-08-01 | 2021-11-19 | 中国中医科学院中药研究所 | Application of tripterine in preparation of medicine for treating complex refractory depression |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| CN105920018B (en) * | 2016-06-15 | 2019-01-11 | 上海市内分泌代谢病研究所 | Celastrol combines the purposes of jamaicin preparation treatment antiobesity agents |
| CN107028953A (en) * | 2017-03-27 | 2017-08-11 | 北京大学 | A kind of stimulant of sympathetic activity |
-
2019
- 2019-04-26 CN CN201910342802.3A patent/CN109908165B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109908165A (en) | 2019-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11110074B2 (en) | Methods of improving the pharmacokinetics of doxepin | |
| JP6271571B2 (en) | Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition | |
| EP2976073B1 (en) | Compositions and methods for producing elevated and sustained ketosis | |
| US11026929B2 (en) | Administration of berberine metabolites | |
| CN105920018B (en) | Celastrol combines the purposes of jamaicin preparation treatment antiobesity agents | |
| EP3445358B1 (en) | Administration of dihydroberberine | |
| JP6462918B2 (en) | Phytoecdysone for use in stabilizing weight after a weight loss diet | |
| CN109908165B (en) | Composition containing tripterine and application thereof | |
| CN102872062A (en) | Medicinal composition for treating or preventing obesity and metabolic syndromes | |
| CN109999044B (en) | Composition containing withaferin A and application thereof | |
| CN101884643B (en) | New purpose of pharmaceutical composition containing pioglitazone and heparin or low molecular heparin | |
| CN106349318B (en) | A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared | |
| CN106727480A (en) | Applications of the Fex-3 in anti-obesity medicine is prepared | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
| US20220079975A1 (en) | Method for mitigation of non-alcoholic fatty liver disease by use of a composition comprising small-molecule fucoidan and fucoxanthin | |
| KR101613252B1 (en) | Compositions for Preventing or Treating Obesity and Fatty Liver Containing Ariginase Inhibitors | |
| US10561167B2 (en) | Hypoglycemic composition and preparation method thereof | |
| WO2014128639A1 (en) | Composition for the treatment of metabolic disorders | |
| CN117695277A (en) | Use of optical isomer compositions of phenylpropionic acid analogs for treating or preventing metabolic disorders | |
| Prajapati et al. | Research Journal of Pharmaceutical, Biological and Chemical Sciences | |
| CN105343072A (en) | Pharmaceutical composition for weight reduction or metabolic syndrome treatment | |
| NZ787374A (en) | Administration of berberine metabolites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |